PBC in the News

Summary News

Back

• Rising awareness and media coverage of liver diseases, particularly PBC, including expert discussions and patient stories on various platforms.
• Promising clinical trial results for new PBC treatments such as linerixibat, seladelpar (Livdelzi), and elafibranor (Iqirvo), showing improvements in symptoms like itch and fatigue.
• Regulatory progress with multiple approvals and conditional authorizations of PBC treatments across Europe, the US, and the UK (e.g., Livdelzi, Iqirvo).
• Ongoing research into the mechanisms and associated conditions of PBC, including links to lymphoma, systemic sclerosis, and gut microbiota.
• Growing investment and milestone payments in the PBC drug development sector, reflecting commercial interest and expanding treatment options.
• Studies highlighting the importance of early diagnosis, personalized treatment plans, and quality of life improvements for PBC patients.
• Concerns over safety and effectiveness of existing treatments, with regulatory bodies declining or revoking approvals (e.g., Ocaliva).
• Educational efforts through art, patient stories, and physician guidance to support awareness and understanding of rare liver diseases like PBC.

News Articles

Back

12/05/2026 Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise - Seeking Alpha

12/05/2026 Can Hypnosis Help Women With Primary Biliary Cholangitis and Fatigue? Read the Study in the May Issue of The American Journal of Gastroenterology | Newswise - Newswise

09/05/2026 New therapies for primary biliary cholangitis - springermedicine.com

05/05/2026 TV Reporter Living with 2 Chronic Diseases Will Receive Liver Donation from Longtime Viewer - People.com

05/05/2026 UK Regulator Clears Treatment for PBC-Related Itch - Medscape

05/05/2026 Fenofibrate-UDCA Combination Therapy Safe and Effective for Primary Biliary Cholangitis - Cleveland Clinic

04/05/2026 Emerging Sub-Segments Transforming the Primary Biliary Cholangitis Therapeutics Market Landscape - openPR.com

04/05/2026 Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis - Business Wire

04/05/2026 From dive trips to a transplant: One woman’s battle with a rare autoimmune liver disease - CNA Lifestyle

03/05/2026 Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Yahoo Finance

01/05/2026 MHRA approves Linerixibat (Lynavoy) for the treatment of itch due to biliary tract disease - GOV.UK

15/04/2026 Off-label fenofibrate improves liver health in PBC patients: Study - Liver Disease News

14/04/2026 Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics - Frontiers

10/04/2026 How PBC Differs From Liver Cirrhosis - WebMD

03/04/2026 Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial - Wiley Online Library

02/04/2026 Molecular mechanisms underlying T cell subset imbalance and precision therapeutic targets in primary biliary cholangitis - Frontiers

31/03/2026 The impact of male sex on outcomes in primary biliary cholangitis - Nature

23/03/2026 FDA Approves Lynavoy for PBC-Associated Pruritus - Gastroenterology & Endoscopy News

22/03/2026 FDA Approves First Drug for Cholestatic Pruritus in Primary Biliary Cholangitis - Medical Dialogues

20/03/2026 Protect Your Well-Being With Primary Biliary Cholangitis - Everyday Health

20/03/2026 FDA approves treatment for debilitating itch in rare liver disease - Managed Healthcare Executive

19/03/2026 FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis - The American Journal of Managed Care

19/03/2026 FDA approves first drug for itch due to primary biliary cholangitis - FirstWord Pharma

19/03/2026 FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis - Pharmacy Times

19/03/2026 After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease - Fierce Pharma

19/03/2026 FDA OKs First Drug for Liver Disease-Related Pruritus - MedPage Today

19/03/2026 FDA OKs linerixibat, now Lynavoy, as first US treatment for itch in PBC - Liver Disease News

18/03/2026 Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Diagnostic Challenge in a Sri Lankan Patient - Cureus

09/03/2026 Alfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decision - European Biotechnology Magazine

09/03/2026 Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision - MedCity News

04/03/2026 New PBC therapy found to reduce liver scarring after 1 year in US trial - Liver Disease News

11/02/2026 Primary biliary cholangitis–associated osteoporosis: contemporary review of pathogenesis and management - EurekAlert!

11/02/2026 Noninvasive combo tests for liver damage could replace biopsies in PBC - Liver Disease News

28/01/2026 Could the sun lower PBC risk? Study explores benefits of UV exposure. - Liver Disease News

22/01/2026 Closing Gaps in PBC Care With Emerging and Established Second-Line Treatments - HCPLive

14/01/2026 Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review - Frontiers

02/01/2026 Seladelpar reduced pruritus in PBC as early as ‘first month, and persisted’ - Healio

02/01/2026 Cholangitis in 2025: Year in Review - HCPLive

23/12/2025 Vitamin D3 attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4/NF-κB mediated M1 macrophage polarization | Scientific Reports - Nature

23/12/2025 New trial at UC Davis Health shows promising results for rare liver disease - University of California - Davis Health

22/12/2025 Treating primary biliary cholangitis - Mayo Clinic Press

17/12/2025 RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis - Science | AAAS

17/12/2025 Compound found in honey reduced inflammation in PBC mice in lab - Liver Disease News

11/12/2025 Current Liver Stiffness Best Predicts PBC Outcomes - EMJ

10/12/2025 Major Developments in the PBC Pruritus Treatment Pipeline - Gastroenterology & Endoscopy News

03/12/2025 Shifts in Blood Lipids Linked to Early Primary Biliary Cholangitis - EMJ

03/12/2025 Linerixibat offers PBC patients fast relief from intense itching in trial - Liver Disease News

02/12/2025 Strength and Spirit: Anna’s Experience with a Rare Liver Disease - Reader's Digest

27/11/2025 Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation - Nature

27/11/2025 Pruritus Exhausts Primary Sclerosing Cholangitis Patients - Medscape

25/11/2025 Meet Wendy, living with PBC - Ipsen

21/11/2025 Patients with Primary Biliary Cholangitis Miss Recommended Monitoring - EMJ

20/11/2025 VIDEO: Iqirvo may stabilize primary biliary cholangitis progression after long-term use - Healio

19/11/2025 Blood group A linked to a higher risk of primary biliary cholangitis - News-Medical

18/11/2025 Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence - PR Newswire

17/11/2025 Reduction in serum IL-31 with linerixibat may be linked to pruritus improvement in PBC - Healio

13/11/2025 VIDEO: Livdelzi appears safe for patients with PBC, advanced liver disease - Healio

12/11/2025 GLISTEN: Linerixibat Improves Biomarkers and Itch in Patients With PBC, With Andreas Kremer, MD, PhD, MHBA - HCPLive

12/11/2025 Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data - Liver Disease News

12/11/2025 VIDEO: Livdelzi demonstrates benefit in PBC regardless of prior fibrate, OCA use - Healio

11/11/2025 Long-Term Elafibranor Treatment Leads to Biochemical, Symptomatic Improvements in PBC - HCPLive

10/11/2025 Seladelpar Staves Off Liver Stiffness in PBC - Medscape

10/11/2025 Elafibranor Treatment Fatigue Improvement - Gastroenterology & Endoscopy News

09/11/2025 Elafibranor Benefits Fatigue-Related Pathways Linked to Mitochondrial Function in PBC - HCPLive

08/11/2025 Seladelpar’s Long-Term Benefit for Pruritus in PBC, With Gideon Hirschfield, FRCP, PhD - HCPLive

05/11/2025 VIDEO: New therapies emerging in primary biliary cholangitis - Healio

05/11/2025 Most recent liver stiffness test best predicts risk of PBC progression - Liver Disease News

05/11/2025 Gilead’s Research Scholars Program Supports New Investigations into Rare Liver Disease - Gilead Sciences

30/10/2025 Ipsen at The Liver Meeting 2025 - Ipsen

27/10/2025 Exploring primary biliary cholangitis - Healio

24/10/2025 Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace

22/10/2025 Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER) - Wiley Online Library

15/10/2025 Women with PBC may be at high risk of disease flares after childbirth - Liver Disease News

14/10/2025 Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia - Nature

10/10/2025 Bezafibrate for primary biliary cholangitis: time to act on the evidence - Nature

09/10/2025 Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis - Cureus

07/10/2025 Linerixibat Reduces Itching in PBC - Medscape

03/10/2025 Non-Response to Obeticholic Acid May Predict Clinical Outcomes in Primary Biliary Cholangitis - Medscape

01/10/2025 PBC worst for life quality among autoimmune liver diseases: Study - Liver Disease News

17/09/2025 PBC treatment Ocaliva leaves U.S. market amid safety concerns - Liver Disease News

15/09/2025 Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy - Frontiers

12/09/2025 Liver Disease Drug Pulled From the Market - MedPage Today

11/09/2025 Ocaliva for PBC Withdrawn From US Market - Medscape

11/09/2025 Intercept Voluntarily Withdraws Obeticholic Acid (Ocaliva) for PBC From US Market - HCPLive

10/09/2025 Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma

10/09/2025 September's PBC Awareness Month raises support for a rare liver disease - Liver Disease News

08/09/2025 Progress in PBC, PSC: Key Updates in Cholestatic Liver Disease Care With Ann Moore, NP - HCPLive

01/09/2025 Beyond tired: Understanding fatigue in Primary Biliary Cholangitis - Ipsen

01/09/2025 Zydus to file for PBC drug approval, but fierce competition looms - Clinical Trials Arena

29/08/2025 Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis - PR Newswire

26/08/2025 An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis - Nature

19/08/2025 FDA Approves Wegovy for a Severe Liver Disease Known as MASH - HealthCentral

07/08/2025 Dendritic Cell-Depleted Mice Develop the Autoimmune Biliary Disease That Serologically and Pathogenically Models Human Primary Biliary Cholangitis - Wiley Online Library

03/08/2025 Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics - Frontiers

02/07/2025 Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis - Nature

02/07/2025 Hepatic Encephalopathy Induced by Small Bowel Obstruction in a Patient With Primary Biliary Cholangitis - Cureus

30/06/2025 Treatment of pruritus in primary biliary cholangitis - Clínica FEHV

25/06/2025 EMA to review linerixibat for primary biliary cholangitis-related itch - Liver Disease News

20/06/2025 Novel Therapies for Adults With Primary Biliary Cholangitis - Medscape Reference

12/06/2025 Primary biliary cholangitis and the narrowing gap towards optimal disease control - The Lancet